A plan to slash drug review times at the Food and Drug Administration is sparking deep concerns among agency staffers and ...
A new review suggests that the FDA usually followed the science, not politics, when making key decisions about mifepristone.
2don MSN
Legal questions swirl around FDA's new expedited drug program, including who should sign off
A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...
Study: FDA regulation of abortion drug mifepristone from 2011 to 2023 shaped by evidence and caution
An analysis of internal Food and Drug Administration documents by researchers at the Johns Hopkins Bloomberg School of Public Health finds that the agency generally followed cautious and ...
PROVIDENCE, R.I., Dec. 8, 2025 /PRNewswire/ -- EpiVax, Inc., with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators ...
MedPage Today on MSN
FDA Has Taken Cautious Approach With Mifepristone, Review Suggests
Three key themes emerged across the mifepristone documents: consistent safety findings, lack of ideological bias in staff ...
The Trump administration's elevation of a vaccine skeptic to lead a high-profile office within the Food and Drug Administration is raising alarm among multiple senior FDA officials, who told CBS News ...
Stocktwits on MSN
GH Research stock grabs retail spotlight ahead of FDA update on depression treatment
GH Research is scheduled to update on the FDA status of GH001 and outline its global Phase 3 plans for treatment-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback